arrow
M

Markus Boehm

Pfizer
H指数:31
被引数:8,219

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Discovery of small molecule modulators of the thin filament that alter the contractile profile in a hypertrophic cardiomyopathy engineered tissue model

在肥厚型心肌病工程组织模型中,发现可改变收缩特性的细丝小分子调节剂

2025-11-130
OAAI
Discovery of the Potent and Selective MC4R Antagonist PF-07258669 for the Potential Treatment of Appetite Loss
2023-02-1915
PRE
Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis
2022-11-0214
PRE
Discovery of a Novel Small-Molecule Modulator of C-X-C Chemokine Receptor Type 7 as a Treatment for Cardiac Fibrosis
2018-04-0822
PREAI
Discovery of Potent and Orally Bioavailable Macrocyclic Peptide-Peptoid Hybrid CXCR7 Modulators
2017-10-3059
OAAI
Discovery and Preclinical Characterization of 6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-carboxylic Acid (PF-06409577), a Direct Activator of Adenosine Monophosphate-activated Protein Kinase (AMPK), for the Potential Treatment of Diabetic Nephropathy

发现和临床前表征6-氯-5-[4-(1-羟基环丁基) 苯基]-1h-吲哚-3-羧酸 (PF-06409577),一磷酸腺苷激活的蛋白激酶 (AMPK) 的直接激活剂,用于糖尿病肾病的潜在治疗

2016-08-20109
OAAI
Discovery of a Selective Covalent Inhibitor of Lysophospholipase-like 1 (LYPLAL1) as a Tool to Evaluate the Role of this Serine Hydrolase in Metabolism
2016-07-1917
OAAI
Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2)
2015-09-1568
PREAI
Discovery of Selective Small Molecule Inhibitors of Monoacylglycerol Acyltransferase 3
2015-09-0816
PREAI
Personalized pre-clinical trials in BRAF inhibitor resistant patient derived xenograft models of melanoma identify c-Met as an effective second line combination therapy target
2015-08-010
PRE